# Kailera Therapeutics, Inc. (KLRA) stock price

URL: https://funkfolio.com/stock/KLRA

> Kailera Therapeutics, Inc. (KLRA) trades at $12.20 and is worth $1.58B. Valuation against its own history and up to 20 years of financials.

---

## Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics, Inc. (KLRA) is a healthcare company (biotechnology) based in the United States. The share price is $12.20, down 2.94% on the day, which values the company at $1.58B. Price as of 17 Nov 2026, 23:17 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $12.20 −2.94% today
- **Market value:** $1.58B
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 23:17 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Kailera Therapeutics, Inc. in more detail

KLRA trades at -3.1× next year's expected earnings.

In its favour: More cash than debt.

1 of the superinvestors tracked here hold KLRA, including Andrew Spokes (0.1% of the portfolio).

### Superinvestors holding KLRA

1 of the investors tracked here report a position in their latest 13F filing.

- [Andrew Spokes Farallon Capital Management](https://funkfolio.com/gurus/farallon) 0.07% of portfolio · $12.6M · Q3 2026

### Kailera Therapeutics, Inc. (KLRA): questions and answers

**What is Kailera Therapeutics, Inc.'s market cap?**

Kailera Therapeutics, Inc. is valued at $1.58B at a share price of $12.20.

**Does KLRA pay a dividend?**

Kailera Therapeutics, Inc. does not currently pay a regular dividend.

**Which famous investors own KLRA?**

In their latest quarterly filings, Andrew Spokes (0.1% of the portfolio) hold KLRA. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Kailera Therapeutics, Inc. (KLRA) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/KLRA

Underlying data: Yahoo Finance; company filings with the SEC.
